NOD-like receptor pyrin domain-containing 3
NOD-like receptor pyrin domain-containing 3
Overview
NOD-like receptor pyrin domain-containing 3 (NLRP3) is a cytosolic pattern-recognition receptor and a central component of the NLRP3 inflammasome. In innate immune signaling, NLRP3 helps sense diverse cellular stressors and danger-associated signals, leading to inflammasome assembly and downstream activation of caspase-1, with subsequent maturation of pro-inflammatory cytokines such as interleukin-1β. Because of this role, NLRP3 is widely studied as a mediator of sterile inflammation, metabolic inflammation, neuroinflammation, and tissue injury.
In biomedical research, NLRP3 is frequently investigated as a therapeutic target rather than as a standalone biomarker. Recent studies in the provided corpus place NLRP3 within pathways such as TLR4/NF-κB/NLRP3, TLR4-dependent inflammasome signaling, AMPK-mTOR, and HSP90-mediated protein stability. These studies collectively support the view that NLRP3 integrates upstream inflammatory cues and contributes to disease progression in interstitial cystitis/bladder pain syndrome, epilepsy-associated neuroinflammation, steatohepatitis, osteoporosis, ischemia/reperfusion injury, hyperuricemic nephropathy, and other inflammatory conditions.
Focus of Latest Publications
Recent publications continue to position NOD-like receptor pyrin domain-containing 3 (NLRP3) as a central inflammatory target across diverse disease models. Several studies evaluated strategies that suppress NLRP3 inflammasome activation to reduce tissue injury and inflammatory signaling. In dextran sulfate sodium-induced colitis, donkey milk exosomes were reported to deliver eca-miR-148a, which directly targeted the NLRP3 3'UTR and suppressed the NLRP3-Caspase-1-IL-18 axis, alongside improvements in intestinal barrier integrity, cytokine profiles, oxidative stress, and gut microbiota composition. In hyperuricemic nephropathy, p-coumaric acid was investigated as a means to target Cathepsin B and rescue WWP1-dependent proteasomal degradation of NLRP3, although the abstract provided does not include the full experimental outcomes. In osteoporosis-related osteoblast injury, betulinic acid reduced NLRP3, ASC, and caspase-1 expression, lowered inflammatory mediators, and improved osteogenic differentiation, with the effect linked to autophagy activation through the AMPK/mTOR pathway.
Other studies examined NLRP3 in neurological and age-related inflammatory disorders. In aged mice, liraglutide alleviated postoperative cognitive impairment by activating the GLP-1R/NRF2 pathway, reducing reactive oxygen species, and suppressing NLRP3 inflammasome components; these effects were reversed by the NRF2 inhibitor ML385 and were dependent on microglia. Thymol nanoparticles also improved oxaliplatin-induced cognitive impairment in rats, with reported modulation of oxidative stress, endoplasmic reticulum stress, and NLRP3 inflammasome signaling. In vascular dementia models, the traditional formula Naokang II decoction was analyzed by network pharmacology and in vitro validation, identifying NLRP3 as a core target in microglia; the coumarin Herniarin showed the strongest docking affinity to NLRP3 and downregulated TLR2, NLRP3, ASC, and CASP1 in microglial cells.
NLRP3 was also implicated in aging and senescence-associated inflammation. A study of Nlrp3 haploinsufficiency in mice found that partial reduction of NLRP3, rather than being uniformly protective, could unmask compensatory NLRP1 overexpression and a hybrid NLRP1-NLRP3 inflammasome interaction that drove accelerated inflammatory aging by 16 months of age. This work suggested that partial NLRP3 inhibition may have unintended consequences and that broader inflammasome targeting could be more effective for age-related disease. In ovarian granulosa cells from aged patients, NPY1R overexpression activated CREB signaling and increased IL-6 and NLRP3 expression, contributing to ferroptosis, mitochondrial dysfunction, and ovarian aging. In a separate biomaterials study, MCC950, a selective NLRP3 inhibitor, was incorporated into silk microgel-hydrogel scaffolds; the construct retained bioactivity, reduced NLRP3 expression around implants, decreased fibrous capsule formation, and increased cellular infiltration in vivo, supporting a pro-regenerative immune microenvironment.
Across these publications, NLRP3 emerges as a convergent node linking oxidative stress, cytokine production, pyroptosis, fibrosis, and tissue remodeling. The studies collectively highlight multiple intervention modes, including miRNA delivery, natural products, small-molecule inhibitors, hormone-like agonists, and biomaterial-based local drug delivery. While most reports describe suppression of NLRP3 as beneficial, the aging study underscores that the biological consequences of partial NLRP3 inhibition may be context dependent, especially when compensatory inflammasome pathways are engaged.